arrow
V

Vlad Ratziu

sorbonne-universite
H指数:107
被引数:6.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study

作者更正:MASLD中脂肪性肝炎和纤维化成像及血清诊断生物标志物的前瞻性验证:LITMUS成像研究

2026-11-190
OAAI
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study

MASLD中脂肪性肝炎和纤维化影像学及血清学诊断生物标志物的前瞻性验证:LITMUS影像学研究

2026-07-240
OA
Health-care burden of metabolic dysfunction-associated steatotic liver disease in European tertiary-care outpatient clinics (CONSTANS): a prospective multicentre cohort study

欧洲三级保健门诊中代谢功能障碍相关脂肪性肝病的医疗负担(CONSTANS):一项前瞻性多中心队列研究

2026-01-010
OAAI
Corrigendum to ‘Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management’ [JHEP Reports (2026) 8; 101798; https://doi.org/10.1016/j.jhepr.2026.101798]

更正:‘脂肪肝疾病轨迹:关于多学科方法进行筛查和患者管理的EASL整体指南’ [JHEP Reports (2026) 8; 101798; https://doi.org/10.1016/j.jhepr.2026.101798]

2026-01-010
OA
RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis

RIPK1抑制可减轻原发性硬化性胆管炎的胆管损伤和纤维化。

2025-12-170
OA
Adipocyte-specific Mlkl knockout mitigates obesity-induced metabolic dysfunction by enhancing mitochondrial functions

脂肪细胞特异性Mlkl基因敲除通过增强线粒体功能缓解肥胖诱导的代谢功能障碍

2025-10-060
OA
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease

代谢性及酒精性肝病中的临床试验设计、生物标志物和终点指标

2025-09-260
PRE
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis

通过司美格鲁肽对代谢功能障碍相关脂肪性肝炎中代谢、炎症和纤维化通路的调控

2025-07-210
OAAI